December 12, 2023 02:19 PM ESTUpdated December 15, 12:14 PM
R&D

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Ayisha Sharma

News Reporter

Dizal said its pe­riph­er­al T-cell lym­phoma drug can­di­date showed pos­i­tive ef­fi­ca­cy and safe­ty in a Phase II reg­is­tra­tional tri­al, paving the way for a US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times